Drug Approval | May 01, 2025
USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility
The Subsidiary has received one inspectional observation in Form 483
The Subsidiary has received one inspectional observation in Form 483
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
Alembic Pharmaceuticals commissions new facility at Pithampur
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
The company has posted net profit of Rs. 406.7 crores for the Financial Year ended March 31, 2025
This approval authorizes the company to export Ibuprofen to the Chinese markets
Subscribe To Our Newsletter & Stay Updated
